Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1287.7, up 0.02% on the day ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr. Reddy's Laboratories Ltd. closed 8.46% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Best case scenario, Semaglutide can garner $500 million sales in FY27, HSBC said. It added that Dr Reddy's will be among the ...